Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio Technology General - BTGC -- Ignore unavailable to you. Want to Upgrade?

To: KAF who wrote (1962)	12/29/1999 6:06:00 PM
From: Area51	Read Replies (1) \| Respond to of 2028

I like this CBS marketwatch interpretation of the news better than mine (If the CBS market watch interpretation is true they should hire the copy writer to write their press releases): cbs.marketwatch.com Bio-Technology General said it may earn as little as half as analysts expected due to problems in moving its drug, Oxandrin. The company expects to earn 5 to 8 cents per share in its fourth quarter, down from a dime in the same quarter last year. Analysts expected the company (BTGC: news, msgs) to earn 9 cents per share. Ahead of the warning, Bio-Technology General shares dropped 15/16 to 14 9/16.